AK-US-001-0107
Brief description of study
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of EFX in subjects with noninvasively diagnosed NASH/NAFLD. Subjects will be dosed QW with EFX 50 mg or placebo for up to 52 weeks. The safety and tolerability of EFX will be assessed during the study through the reporting of extent of exposure, adverse events (AEs), clinical laboratory tests, ECGs, Bone Mineral Density (BMD), vital sign assessments, body weight, and medication usage.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
